Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indivior Knew Suboxone Film Did Not Have Greater Child Safety Than Tablet, Grand Jury Claims

Executive Summary

Indictment alleges Indivior falsely cited concerns about pediatric exposure to tablets in discontinuing the formulation; FDA official says company tried to mislead agency and bar competition for Suboxone.

You may also be interested in...



Clinical Data Fraud Involving CROs Attracting US Justice Department Attention

Submission of manipulated clinical data to support product approval is a ‘major concern’ for the DoJ, consumer protection branch director Gusav Eyler says, adding that some of the problems relate to outsourcing of trials. Also, DoJ and HHS OIG are using data analytics to identify outliers in prescribing and reimbursement claims.

Indivior Submits Products For Approval Outside The US, Where Pressures Mount

Indivior is working on receiving ex-US approvals for its opioid abuse treatment products and building its cash reserves but faces future uncertainty over US generic competition and a US Department of Justice legal action.

FTC's First Product Hopping Complaint Targets Safety Claims For Suboxone Film Formulation

Commission files complaint as it reaches $50m settlement with Reckitt Benckiser.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS125091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel